申请人:Teijin Pharma Limited
公开号:EP3176165A1
公开(公告)日:2017-06-07
There are provided crystals of 2-[4-(2,2-dimethylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid which is useful as a therapeutic agent or prophylactic agent for gout, hyperuricemia and the like.
提供了 2-[4-(2,2-二甲基丙氧基)-3-(1H-1,2,3,4-四唑-1-基)苯基]-4-甲基-1,3-噻唑-5-羧酸晶体,该晶体可用作痛风、高尿酸血症等的治疗剂或预防剂。